Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konstantinos Papamichael

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
World Journal of Gastroenterology|May 7, 2015
Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel diseaseKonstantinos Papamichael, Severine Vermeire
Journal of Crohn'S & Colitis|February 14, 2016
Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's DiseaseKonstantinos Papamichael, Adam S Cheifetz
Gastroenterology|August 11, 2019
Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?Konstantinos Papamichael, Adam S Cheifetz
World Journal of Gastroenterology|October 5, 2017
Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapyKonstantinos Papamichael, Adam S Cheifetz
Journal of Crohn'S & Colitis|November 26, 2019
Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future PerspectivesKonstantinos Papamichael, Adam S Cheifetz
Frontline Gastroenterology|August 26, 2017
Use of anti-TNF drug levels to optimise patient managementKonstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|December 8, 2017
Response to ReininkKonstantinos Papamichael, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 28, 2020
Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel DiseaseKonstantinos Papamichael, Adam S Cheifetz
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2022
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodiesKonstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|February 22, 2017
Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF TherapyKonstantinos Papamichael, Adam S Cheifetz
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
World Journal of Gastroenterology|May 7, 2015
Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel diseaseKonstantinos Papamichael, Severine Vermeire
Journal of Crohn'S & Colitis|February 14, 2016
Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's DiseaseKonstantinos Papamichael, Adam S Cheifetz
Gastroenterology|August 11, 2019
Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?Konstantinos Papamichael, Adam S Cheifetz
World Journal of Gastroenterology|October 5, 2017
Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapyKonstantinos Papamichael, Adam S Cheifetz
Journal of Crohn'S & Colitis|November 26, 2019
Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future PerspectivesKonstantinos Papamichael, Adam S Cheifetz
Frontline Gastroenterology|August 26, 2017
Use of anti-TNF drug levels to optimise patient managementKonstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|December 8, 2017
Response to ReininkKonstantinos Papamichael, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 28, 2020
Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel DiseaseKonstantinos Papamichael, Adam S Cheifetz
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2022
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodiesKonstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|February 22, 2017
Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF TherapyKonstantinos Papamichael, Adam S Cheifetz
Pageof 15